Ryoko Sakai

Ryoko Sakai

Auto-generated profile, based on publicly available information

Ryoko Sakai

Department of Public Health and Epidemiology, Meiji Pharmaceutical University , Tokyo

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2021 in Modern Rheumatology
Verified
Journal Article
Closed access
PDF file
SHSuguru Honda
Suguru Honda
RSRyoko Sakai
Ryoko Sakai
EIEisuke Inoue
Eisuke Inoue
MMMasako Majima
Masako Majima
NKNaoko Konda
Naoko Konda
MHMasayoshi Harigai
Masayoshi Harigai
Objectives: To investigate the risk factors and clinical characteristics of lymphoproliferative disorder (LPD) in Japanese patients with rheumatoid arthritis (RA).Methods: We enrolled patients with RA aged ≥20 years who visited the participating hospitals between April 2011 and July 2011. We investigated the risk factors for LPD using a Cox proportional hazard model and described pathological features and vital prognosis of LPD in patients with RA.Results: We enrolled 9815 patients with the following characteristics at baseline: female 79.4%, median age 63 years; median disease duration 7 years; median DAS28-CRP (3) 3.1; prevalence of MTX use 60.0%. Sixty-eight patients (0.69%) developed LPD in 3-year observation period. Multivariable analysis showed that age by decade (hazard ratio [95% confidence interval], 1.47 [1.18–1.85]) and MTX use at baseline (2.35 [1.25–4.42] for ≤8 mg/week, 4.39 [2.07–9.32] for >8 mg/week versus non-use) were significant risk factors of LPD. Of 55 patients with pathological diagnosis, diffuse large B cell lymphoma was the most frequent (54%). The 5-year mortality of LPD was 24%. The major cause of death was lymphoma (81%).Conclusion: This nationwide study revealed risk factors, clinical characteristics, and prognosis of LPD in the largest number of Japanese patients with RA.

17 April 2018 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RSRyoko Sakai
Ryoko Sakai
SKShoko Kasai
Shoko Kasai
FHFumio Hirano
Fumio Hirano
SHSayoko Harada
Sayoko Harada
MKMari Kihara
Mari Kihara
MHMasayoshi Harigai
Masayoshi Harigai

17 June 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
RSRyoko Sakai
Ryoko Sakai
ETEiichi Tanaka
Eiichi Tanaka
EIEisuke Inoue
Eisuke Inoue
MHMasayoshi Harigai
Masayoshi Harigai
Objectives To compare the risk of cardiovascular events among Janus kinase inhibitors (JAKIs), biological disease-modifying antirheumatic drugs (bDMARDs) (tumour necrosis factor inhibitors (TNFIs) and non-TNFIs) and methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA). Methods Using Japanese claims data, patients with RA were enrolled in this study if they had at least one ICD-10 code (M05 or M06), were new users of JAKIs, bDMARDs or MTX between July 2013 and July 2020 and being 18 years old or older. The incidence rate (IR), IR ratio and adjusted hazard ratio (aHR (95% CI)) of cardiovascular events including venous thromboembolism, arterial thrombosis, acute myocardial infarction and stroke were calculated. A time-dependent Cox regression model adjusted for patient characteristics at baseline was used to calculate aHR. Results In 53 448 cases, IRs/1000 patient-years of the overall cardiovascular events were 10.1, 6.8, 5.4, 9.1 and 11.3 under the treatments with JAKIs, bDMARDs, TNFIs, non-TNFIs and MTX, respectively. The adjusted HRs of JAKIs for overall cardiovascular events were 1.7 (1.1 to 2.5) versus TNFIs without MTX and 1.7 (1.1 to 2.7) versus TNFIs with MTX. Conclusions Among patients with RA, individuals using JAKIs had a significantly higher risk of overall cardiovascular events than TNFIs users, which was attributed to the difference in the risk between JAKIs and TNFIs versus MTX. These data should be interpreted with caution because of the limitations associated with the claims database.

23 July 2019 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
RSRyoko Sakai
Ryoko Sakai
ETEiichi Tanaka
Eiichi Tanaka
HNHirokazu Nishina
Hirokazu Nishina
MSMasayoshi Suzuki
Masayoshi Suzuki
HYHisashi Yamanaka
Hisashi Yamanaka
MHMasayoshi Harigai
Masayoshi Harigai

24 August 2020 in Lupus
Verified
Journal Article
Closed access
PDF file
RSRyoko Sakai
Ryoko Sakai
SHSuguru Honda
Suguru Honda
ETEiichi Tanaka
Eiichi Tanaka
MMMasako Majima
Masako Majima
NKNaoko Konda
Naoko Konda
MHMasayoshi Harigai
Masayoshi Harigai
Objective: To compare the risk of hospitalized infection (HI) between users and non-users of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE). Methods: Using claims data, patients were defined as SLE cases by the following criteria: 1) they had at least one SLE diagnostic code; 2) they had a prescription for specific drugs, including corticosteroids, steroid pulse therapy, and immunosuppressive drugs; and 3) they were at least 16 years old between September 2015 and July 2017 (n = 17,483). The SLE cases with at least one prescription for HCQ were defined as the HCQ group (n = 1,431), while the others were defined as the non-HCQ group. Among the SLE cases, propensity score-matched cases were observed for 1 year (n = 1,095 in each group). Results: The median age and proportion of female patients in both groups were about 42 years and 88%, respectively. The proportions of cases with HIs were similar (HCQ group, 4.5%; non-HCQ group, 5.6%; p = 0.240, McNemar test). The hazard ratio of the HCQ group for HIs after adjusting for patients’ characteristics was not significant at 0.9 (0.6–1.3). Conclusion: The use of HCQ was not associated with a risk of HIs in patients with SLE.